Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice.

Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, 66424 Homburg/Saar, Germany.
Circulation (Impact Factor: 14.95). 06/2008; 117(18):2377-87. DOI: 10.1161/CIRCULATIONAHA.107.746537
Source: PubMed

ABSTRACT Elevated heart rate is associated with increased cardiovascular morbidity. We hypothesized that selective heart rate reduction may influence endothelial function and atherogenesis and tested the effects of the I(f) current inhibitor ivabradine in apolipoprotein E-deficient mice.
Male apolipoprotein E-deficient mice fed a high-cholesterol diet were treated with ivabradine (10 mg . kg(-1) . d(-1)) or vehicle for 6 weeks (n=10 per group). Ivabradine reduced heart rate by 13.4% (472+/-9 versus 545+/-11 bpm; P<0.01) but did not alter blood pressure or lipid levels. Endothelium-dependent relaxation of aortic rings was significantly improved in ivabradine-fed animals (P<0.01). Ivabradine decreased atherosclerotic plaque size in the aortic root by >40% and in the ascending aorta by >70% (P<0.05). Heart rate reduction by ivabradine had no effect on the number of endothelial progenitor cells and did not alter aortic endothelial nitric oxide synthase, phosphorylated Akt, vascular cell adhesion molecule-1, or intercellular adhesion molecule-1 expression but decreased monocyte chemotactic protein-1 mRNA and exerted potent antioxidative effects. Ivabradine reduced vascular NADPH oxidase activity to 48+/-6% and decreased markers of superoxide production and lipid peroxidation in the aortic wall (P<0.05). The in vivo effects of ivabradine were absent at a dose that did not lower heart rate, in aortic rings treated ex vivo, and in cultured vascular cells. In contrast to ivabradine, treatment with hydralazine (25 mg . kg(-1) . d(-1) for 6 weeks) reduced blood pressure (-15%) but increased heart rate (37%) and did not improve endothelial function, atherosclerosis, or oxidative stress.
Selective heart rate reduction with ivabradine decreases markers of vascular oxidative stress, improves endothelial function, and reduces atherosclerotic plaque formation in apolipoprotein E-deficient mice.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ivabradine (IVBD), a novel I(f)-channel inhibitor and specific heart rate-lowering agent, is known to have anti-oxidative activity that promotes endothelial function. However, the molecular mechanism through which IVBD acts on cardiac function has yet to be elucidated, especially in experimental diabetic animals.
    BMC Cardiovascular Disorders 10/2014; 14(1):150. · 1.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: According to data of the World Health Organization, cardiovascular diseases belong to the leading causes of death worldwide. In addition, the ischemic heart disease is the number one cause of death. Chronic stable angina pectoris is the most frequent symptom or form of the ischemic heart disease. High heart rate appears to play an important role in its patophysiology, since it takes part in the development of the endothelial dysfunction at the atherosclerosis’ onset. Current pharmacotherapy of the stable angina pectoris is limited. The development of ivabradine, which is a selective and specific inhibitor of the If current in the sinus node, enabled new possibilities in its management. Ivabradine’s antianginal properties were tested in many randomised, placebo controlled clinical studies. Nowadays, it is indicated as a second-line therapy for patients, who cannot be treated with betablockers because it would be unsuitable or insufficient with respect to reaching adequate heart rate. The aim of this review is to provide information about the development and mechanism of action of ivabradine, discuss about its possible pleiotropic effects, provide an information about clinical trials with ivabradine, and describe current status of ivabradine in clinical practice. Supported by grant VEGA number 1/0858/11.
    Journal of Clinical Trials. 04/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Preclinical data have demonstrated that heart rate (HR) can directly impact vascular endothelial function, in part, through a shear stress mechanism. This study sought to explore, in humans, the associations between resting heart rate and both shear and endothelial function assessed by flow-mediated dilation (FMD). The brachial artery FMD test was performed in 31 apparently healthy volunteers. Basal (B) and hyperemic (H) shear were quantified two ways using data from the FMD test: the traditional cumulative shear area under the curve up until peak dilation (Shearcum) method, and our novel method of shear summation (Shearsum), which accounts for HR by summing each individual cardiac cycle shear up until peak dilation. Data were grouped by tertiles based on resting HR: low (LHR = 43 – 56 bpm; n = 10), middle (MHR = 58 – 68 bpm; n = 11), and high (HHR = 69–77; n = 10), respectively. Within the LHR group, both B-Shearcum and H-Shearcum were significantly higher (p<0.001) than B-Shearsum and H-Shearsum, respectively, whereas B-Shearcum and H-Shearcum were significantly lower (p<0.001) than B-Shearsum and H-Shearsum in the HHR group. FMD in the LHR group (8.8±0.8%) was significantly greater than both the MHR (5.5±0.8%; p = 0.009) and the HHR group (5.9±0.8%; p = 0.024). These findings demonstrate the existence of a relationship between heart rate and both shear and endothelial function in humans. Moreover, these findings have implications for considering heart rate as an important physiological variable when quantifying shear and performing the FMD test.This article is protected by copyright. All rights reserved
    Experimental physiology 07/2014; · 2.87 Impact Factor


Available from